{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-23-000022","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.612440+00:00","generated_at":"2026-06-15T13:23:08.550056+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Recursion acquires Cyclica ($40M) & Valence ($47.5M); Q1 net loss $65.3M","bullets":["Entered agreements to acquire Cyclica for $40M and Valence for $47.5M, payable in stock; expected Q2 2023 close.","Q1 cash $473.1M; revenue $12.1M (up from $5.3M YoY) driven by Roche-Genentech collaboration.","Net loss $65.3M vs $56.0M Q1 2022; R&D expenses rose to $46.7M on platform expansion.","Phase 2 SYCAMORE trial (REC-994) in CCM: >80% enrolled; top-line data expected H2 2024.","Phase 2/3 POPLAR trial (REC-2282) in NF2-mutated meningiomas; interim safety analysis expected 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-23-000022","json":"https://secwatch.observer/filing/0001601830-23-000022.json","markdown":"https://secwatch.observer/filing/0001601830-23-000022.md","text":"https://secwatch.observer/filing/0001601830-23-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000022/0001601830-23-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000022/rxrx-20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:23:08.550056+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d49fb1279a87f818346a64facfdc3bb045121bf8","claim":"RECURSION PHARMACEUTICALS, INC. reported financial results for first quarter March 31, 2023.","evidence_excerpt":"On May 8, 2023, Recursion Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the first quarter March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000022/0001601830-23-000022-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}